{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:57:28Z","timestamp":1792785448997,"version":"4.5.0"},"reference-count":96,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Faron Pharmaceuticals","id":[{"id":"https:\/\/ror.org\/02kvdh980","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/14737140.2026.2640238","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T01:28:19Z","timestamp":1772760499000},"page":"615-628","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Learning from late-stage trial failures in higher-risk myelodysplastic syndromes: towards adaptive and biomarker-enriched designs"],"prefix":"10.1080","volume":"26","author":[{"given":"Amer M.","family":"Zeidan","sequence":"first","affiliation":[{"name":"Yale School of Medicine and Yale Comprehensive Cancer Center","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Aakko","sequence":"additional","affiliation":[{"name":"Faron Pharmaceuticals Ltd","place":["Turku, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Stahl","sequence":"additional","affiliation":[{"name":"Yale School of Medicine and Yale Comprehensive Cancer Center","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-0902","authenticated-orcid":false,"given":"Jan P.","family":"Bewersdorf","sequence":"additional","affiliation":[{"name":"Yale School of Medicine and Yale Comprehensive Cancer Center","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petri","family":"Bono","sequence":"additional","affiliation":[{"name":"Faron Pharmaceuticals Ltd","place":["Turku, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppo","family":"Huttunen","sequence":"additional","affiliation":[{"name":"Faron Pharmaceuticals Ltd","place":["Turku, Finland"]},{"name":"EstiMates Oy","place":["Turku, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juho","family":"Jalkanen","sequence":"additional","affiliation":[{"name":"Faron Pharmaceuticals Ltd","place":["Turku, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Louramo","sequence":"additional","affiliation":[{"name":"Faron Pharmaceuticals Ltd","place":["Turku, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneel","family":"Nimba","sequence":"additional","affiliation":[{"name":"Faron Pharmaceuticals Ltd","place":["Turku, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joab","family":"Williamson","sequence":"additional","affiliation":[{"name":"Faron Pharmaceuticals Ltd","place":["Turku, Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,4]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.06.004"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70003-8"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0936"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205495"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2021.1889161"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2023.12.008"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542720"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn349"},{"key":"e_1_3_6_12_1","unstructured":"Watts J. Higher-risk myelodysplastic syndromes: lacking treatment advances in over a decade. 2020 [cited 2025 Jul 20]. Available from: https:\/\/wwwonclivecom\/view\/higher-risk-myelodysplastic-syndromes-hr-mds-lacking-treatment-advances-in-over-a-decade"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15082248"},{"key":"e_1_3_6_14_1","unstructured":"Abbvie. AbbVie provides update on VERONA trial for newly diagnosed higher-risk myelodysplastic syndromes. 2025 [cited 2025 Jul 18]. Available from: https:\/\/newsabbviecom\/2025-06-16-AbbVie-Provides-Update-on-VERONA-Trial-for-Newly-Diagnosed-Higher-Risk-Myelodysplastic-Syndromes"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00333-2"},{"key":"e_1_3_6_16_1","first-page":"S180","article-title":"Primary results of the Phase III STIMULUS-MDS2 study of sabatolimab + azacitidine vs placebo + azacitidine as frontline therapy for patients with higher risk MDS or CMML-2","volume":"422284","author":"Zeidan AM","year":"2024","unstructured":"Zeidan AM, Xiao Z, Sanz G, et al. Primary results of the Phase III STIMULUS-MDS2 study of sabatolimab + azacitidine vs placebo + azacitidine as frontline therapy for patients with higher risk MDS or CMML-2. Eur Hematol Assoc. 2024;422284:S180.","journal-title":"Eur Hematol Assoc"},{"key":"e_1_3_6_17_1","unstructured":"ClinicalTrials.gov. Magrolimab + azacitidine versus azacitidine + placebo in untreated participants with myelodysplastic syndrome (MDS) (ENHANCE). 2024. Available from: https:\/\/clinicaltrialsgov\/study\/NCT04313881?tab=results"},{"key":"e_1_3_6_18_1","unstructured":"Gilead. Gilead statement on discontinuation of Phase 3 ENHANCE-3 study in AML. 2024 [cited 2025 Jul 18]. Available from: https:\/\/wwwgileadcom\/company\/company-statements\/2024\/gilead-statement-on-discontinuation-of-phase-3-enhance-3-study-in-aml"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016229"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00009-7"},{"key":"e_1_3_6_21_1","unstructured":"Onconova therapeutics. Annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934. 2020. Available from: https:\/\/wwwsecgov\/Archives\/edgar\/data\/1130598\/000110465921038452\/tm211024-110khtm"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007334"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2510"},{"key":"e_1_3_6_24_1","unstructured":"Aprea. Aprea therapeutics announces results of primary endpoint from Phase 3 trial of eprenetapopt in TP53 mutant myelodysplastic syndromes (MDS). 2020 [cited 2025 Jul 19]. Available from: https:\/\/irapreacom\/news-releases\/news-release-details\/aprea-therapeutics-announces-results-primary-endpoint-phase-3"},{"key":"e_1_3_6_25_1","unstructured":"ClinicalTrials.gov. APR-246 & azacitidine for the treatment of TP53 mutant myelodysplastic syndromes (MDS). 2025 [cited 2025 Jan 8]. Available from: https:\/\/wwwclinicaltrialsgov\/study\/NCT03745716?tab=results"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005487"},{"key":"e_1_3_6_27_1","unstructured":"Garcia-Manero G Bart S McCloskey JK et al. Guadecitabine (SGI-110) vs. treatment choice (TC) in relapsed\/refractory (R\/R) myelodysplastic syndrome (MDS) results of a global randomized Phase 3 study. 2022. Available from: https:\/\/libraryehaweborg\/eha\/2022\/eha2022-congress\/357630\/guillermogarcia-maneroguadecitabine28sgi-11029vstreatmentchoice28tc29inhtml?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Atopic%3D1574%2Asearch%3Dgarcia-manero"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-855221"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29085"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.3102"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2025029727"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3348"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-236"},{"key":"e_1_3_6_34_1","unstructured":"EMA. Guideline on the clinical evaluation of anticancer medicinal products. Available from: https:\/\/wwwemaeuropaeu\/en\/documents\/scientific-guideline\/guideline-clinical-evaluation-anticancer-medicinal-products-revision-6_enpdf. 2023;6"},{"key":"e_1_3_6_35_1","unstructured":"FDA. Clinical trial endpoints for the approval of cancer drugs and biologics. 2018. Available from: https:\/\/wwwfdagov\/media\/71195\/download"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018604"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0269-y"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.24406"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.11.006"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S5203"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.10.002"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2025.103524"},{"key":"e_1_3_6_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1005"},{"key":"e_1_3_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2022.101405"},{"key":"e_1_3_6_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2019000041"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.8687"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24490"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-163098"},{"key":"e_1_3_6_49_1","article-title":"What is the outlook and life expectancy of MDS?","author":"Seymour T","year":"2025","unstructured":"Seymour T. What is the outlook and life expectancy of MDS? MedicalNewtoday. 2025. Available from: https:\/\/www.medicalnewstoday.com\/articles\/319346","journal-title":"MedicalNewtoday"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010417"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02175"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.014"},{"key":"e_1_3_6_53_1","volume-title":"EHA 2024 Congress","author":"Sallman D","year":"2024","unstructured":"Sallman D, Garcia-Manero G, Daver N, et al. Magrolimab (MAGRO) + azacitidine (AZA) vs placebo (PBO) + AZA in patients (PTS) with untreated higher-risk (HR) myelodysplastic syndromes (MDS): phase 3 ENHANCE study final analysis. In: EHA 2024 Congress; Spain; 2024."},{"key":"e_1_3_6_54_1","unstructured":"FDA. Myelodysplastic syndromes: developing drug and biological products for treatment. Guidance for industry. Draft guidance. 2025. Available from: https:\/\/wwwfdagov\/media\/187373\/download"},{"key":"e_1_3_6_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.02.006"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0988"},{"key":"e_1_3_6_57_1","unstructured":"The Japanese Data Center for Hematopoietic Cell Transplantation. Hematopoietic cell transplantation and cellular therapy in Japan 2024 summary slides. 2024 [cited 2025 Jul 20]. Available from: https:\/\/wwwjdchctorjp\/en\/data\/slide\/2024\/"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)02083-X"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025464"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01794"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02341"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.70092"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-235"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13148-018-0476-1"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022009167"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2021.106555"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.04.117"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.23"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-289280"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V110.11.817.817"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S516558"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719847059"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0334"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011304"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.33175"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1081\/BIP-200062277"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1017-7"},{"key":"e_1_3_6_79_1","unstructured":"FDA. Adaptive designs for clinical trials of drugs and biologics guidance for industry. 2019 [cited 2025 Jul 21]. Available from: https:\/\/wwwfdagov\/media\/78495\/download"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.02.807"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-024-02174-w"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/bimj.201600026"},{"key":"e_1_3_6_83_1","unstructured":"ICH. Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. 2019 [cited 2025 Jul 21]. Available from: https:\/\/databaseichorg\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203pdf"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-12-S1-A2"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/19466315.2021.1914717"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.10130"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0739-3"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1177\/1740774513497293"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6086"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1177\/09622802251348183"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2016.01.001"},{"key":"e_1_3_6_92_1","unstructured":"FDA. Use of Bayesian methodology in clinical trials of drug and biological products: guidance for industry (draft). 2026. Available from: https:\/\/wwwfdagov\/media\/190505\/download"},{"key":"e_1_3_6_93_1","unstructured":"ICH. Adaptive designs for clinical trials E20. 2025 [cited 2025 Jul 21]. Available from: https:\/\/wwwichorg\/page\/efficacy-guidelines#19-1"},{"key":"e_1_3_6_94_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513749"},{"key":"e_1_3_6_95_1","unstructured":"EMA. Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. 2007 [cited 2025 Jul 21]. Available from: https:\/\/wwwemaeuropaeu\/en\/documents\/scientific-guideline\/reflection-paper-methodological-issues-confirmatory-clinical-trials-planned-adaptive-design_enpdf"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014865"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30903"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101056"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2640238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737140.2026.2640238","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2640238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:15:19Z","timestamp":1791443719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2026.2640238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,4]]},"references-count":96,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/14737140.2026.2640238"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2026.2640238","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}